About this trial

PAD-VRCE is an observational, cross-sectional, two arm study aimed at determining if the presence of peripheral artery disease (PAD) can influence the number of circulating regenerative cells in blood. From peripheral blood samples, circulating progenitor cell content will be assessed via flow cytometry and compared between individuals with PAD and individuals without PAD. Ultimately, this study plans to evaluate the relationship between PAD, vascular regenerative cell exhaustion and overall cardiovascular health.

Eligibility criteria

Qualifiers

Clinically significant/symptomatic PAD (defined as symptomatic claudication with and an ankle brachial index of less than 0.85).

No history of PAD.

Willing and able to provide written informed consent and comply with study procedures.

Disqualifiers

Unable or unwilling to provide written informed consent or to provide a peripheral blood sample.

Any life-threatening disease expected to result in death within two years.

Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.

Uncontrolled hypertension.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

40 Participants
are grouped into 2 trial groups

Locations

2
North York Diagnostic and Cardiac CentreM6B1N6, North YorkOntario, Canada
Diagnostic Assessment CentreM1S4N6, Scarborough VillageOntario, Canada

Sponsors and collaborators

Canadian Medical and Surgical Knowledge Translation Research Group

Lead sponsor